An elevated PSA level in the blood may indicate prostate cancer but does not allow for a definitive diagnosis. Where there is ...

An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis.

PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in the Journal of Nuclear Medicine. By applying the ...

The scan found 91 percent of dangerous tumors and correctly cleared most men who didn’t need a biopsy at all.

The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY ...

The US Food and Drug Administration (FDA) has approved flotufolastat fluorine-18 (Posluma), a radiopharmaceutical for use with positron-emission tomography (PET) in prostate cancer. The product is ...

The 2026 ProsTIC annual meeting featured a Keynote Address presentation by Dr. Alicia Morgans discussing PSMA PET/CT and the ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of the fastest-growing segments in molecular imagingBEDMINSTER, N.J., Sept. 15, ...

Prostate zonal anatomy is best demonstrated with MRI. On T2-weighted sequences, the normal prostate can be divided into the peripheral zone, which shows high signal intensity owing to its high water ...